Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia
Background: Low-risk gestational trophoblastic neoplasia could be cured in the case of appropriate management with single-agent chemotherapy. This study was carried out to compare the efficacy of single-dose methotrexate versus Actinomycin-D in low-risk gestational trophoblastic neoplasia to analyze...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2023-01-01
|
| Series: | Caspian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://caspjim.com/article-1-3287-en.html |
| _version_ | 1797957134382530560 |
|---|---|
| author | Leila Mousavi Seresht Marjaneh Farazestanian Zohreh Yousefi |
| author_facet | Leila Mousavi Seresht Marjaneh Farazestanian Zohreh Yousefi |
| author_sort | Leila Mousavi Seresht |
| collection | DOAJ |
| description | Background: Low-risk gestational trophoblastic neoplasia could be cured in the case of appropriate management with single-agent chemotherapy. This study was carried out to compare the efficacy of single-dose methotrexate versus Actinomycin-D in low-risk gestational trophoblastic neoplasia to analyze the most effective agent.
Methods: This retrospective cohort study was conducted on the medical record of 170 cases with the diagnosis of low-risk gestational trophoblastic neoplasia from 2012 to 2019 to evaluate the response rate of single-dose weekly-methotrexate versus biweekly-Actinomycin-D.
Results: Single agent chemotherapy was required in 170 patients with final risk score of less than 7. Among the 100 cases under weekly-methotrexate therapy, 29 patients were required second-line chemotherapy with Actinomycin-D and combination therapy which means complete remission of 71% with methotrexate, in comparison with 78.5% in the other group. Resistance was mostly seen in patients with documented choriocarcinoma in histology who had not received timely diagnosis and treatment.
Conclusion: Individualized decision in the management of low-risk gestational trophoblastic neoplasia cases, based on histology, HCG, and history is the corn stone in successful treatment. |
| first_indexed | 2024-04-10T23:59:33Z |
| format | Article |
| id | doaj.art-041c43485ae342abad151329e092996e |
| institution | Directory Open Access Journal |
| issn | 2008-6164 2008-6172 |
| language | English |
| last_indexed | 2024-04-10T23:59:33Z |
| publishDate | 2023-01-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Caspian Journal of Internal Medicine |
| spelling | doaj.art-041c43485ae342abad151329e092996e2023-01-10T05:28:09ZengBabol University of Medical SciencesCaspian Journal of Internal Medicine2008-61642008-61722023-01-01141108111Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasiaLeila Mousavi Seresht0Marjaneh Farazestanian1Zohreh Yousefi2 Department of Gynecology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran Department of Gynecology and Oncology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Department of Gynecology and Oncology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Background: Low-risk gestational trophoblastic neoplasia could be cured in the case of appropriate management with single-agent chemotherapy. This study was carried out to compare the efficacy of single-dose methotrexate versus Actinomycin-D in low-risk gestational trophoblastic neoplasia to analyze the most effective agent. Methods: This retrospective cohort study was conducted on the medical record of 170 cases with the diagnosis of low-risk gestational trophoblastic neoplasia from 2012 to 2019 to evaluate the response rate of single-dose weekly-methotrexate versus biweekly-Actinomycin-D. Results: Single agent chemotherapy was required in 170 patients with final risk score of less than 7. Among the 100 cases under weekly-methotrexate therapy, 29 patients were required second-line chemotherapy with Actinomycin-D and combination therapy which means complete remission of 71% with methotrexate, in comparison with 78.5% in the other group. Resistance was mostly seen in patients with documented choriocarcinoma in histology who had not received timely diagnosis and treatment. Conclusion: Individualized decision in the management of low-risk gestational trophoblastic neoplasia cases, based on histology, HCG, and history is the corn stone in successful treatment.http://caspjim.com/article-1-3287-en.htmlactinomycingestational trophoblastic neoplasiamethotrexateoutcomesingle-agent chemotherapy. |
| spellingShingle | Leila Mousavi Seresht Marjaneh Farazestanian Zohreh Yousefi Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia Caspian Journal of Internal Medicine actinomycin gestational trophoblastic neoplasia methotrexate outcome single-agent chemotherapy. |
| title | Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia |
| title_full | Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia |
| title_fullStr | Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia |
| title_full_unstemmed | Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia |
| title_short | Comparison between single-agent chemotherapy in low-risk gestational trophoblastic neoplasia |
| title_sort | comparison between single agent chemotherapy in low risk gestational trophoblastic neoplasia |
| topic | actinomycin gestational trophoblastic neoplasia methotrexate outcome single-agent chemotherapy. |
| url | http://caspjim.com/article-1-3287-en.html |
| work_keys_str_mv | AT leilamousaviseresht comparisonbetweensingleagentchemotherapyinlowriskgestationaltrophoblasticneoplasia AT marjanehfarazestanian comparisonbetweensingleagentchemotherapyinlowriskgestationaltrophoblasticneoplasia AT zohrehyousefi comparisonbetweensingleagentchemotherapyinlowriskgestationaltrophoblasticneoplasia |